Lyell Immunopharma

Lyell Immunopharma is a South San Francisco clinical-stage biotechnology company and strategic investor in U.S. cell and gene therapy companies. Alongside developing next-generation CAR T-cell candidates for cancer, it has participated in Series A and later-stage venture financings, including lead and co-lead roles, across biotechnology, life sciences, oncology and pharmaceuticals. The profile is most relevant for U.S.-based cancer therapeutics and cell therapy founders seeking strategic capital from an operating life sciences company.